CA2905671A1 - Omega-3 pentaenoic acid compositions and methods of use - Google Patents
Omega-3 pentaenoic acid compositions and methods of use Download PDFInfo
- Publication number
- CA2905671A1 CA2905671A1 CA2905671A CA2905671A CA2905671A1 CA 2905671 A1 CA2905671 A1 CA 2905671A1 CA 2905671 A CA2905671 A CA 2905671A CA 2905671 A CA2905671 A CA 2905671A CA 2905671 A1 CA2905671 A1 CA 2905671A1
- Authority
- CA
- Canada
- Prior art keywords
- alternatively
- dpa
- epa
- dha
- fatty acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Edible Oils And Fats (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361780948P | 2013-03-13 | 2013-03-13 | |
US61/780,948 | 2013-03-13 | ||
PCT/US2013/075661 WO2014143272A1 (en) | 2013-03-13 | 2013-12-17 | Omega-3 pentaenoic acid compositions and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2905671A1 true CA2905671A1 (en) | 2014-09-18 |
Family
ID=51537458
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2905671A Abandoned CA2905671A1 (en) | 2013-03-13 | 2013-12-17 | Omega-3 pentaenoic acid compositions and methods of use |
CA2905795A Abandoned CA2905795A1 (en) | 2013-03-13 | 2014-03-12 | Compositions comprising docosapentaenoic acid and methods of use |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2905795A Abandoned CA2905795A1 (en) | 2013-03-13 | 2014-03-12 | Compositions comprising docosapentaenoic acid and methods of use |
Country Status (4)
Country | Link |
---|---|
EP (2) | EP2968246A4 (ja) |
JP (2) | JP2016518315A (ja) |
CA (2) | CA2905671A1 (ja) |
WO (4) | WO2014143272A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6750831B2 (ja) * | 2014-12-15 | 2020-09-02 | ディーエスエム アイピー アセッツ ビー.ブイ.Dsm Ip Assets B.V. | 非アルコール性脂肪性肝疾患の処置 |
CN106692973A (zh) * | 2015-11-13 | 2017-05-24 | 深圳君圣泰生物技术有限公司 | 一种组合物及其用途、药物制剂 |
CA3023648C (en) * | 2016-05-10 | 2023-11-28 | Shenzhen Hightide Biopharmaceutical, Ltd. | Pharmaceutical composition of berberine with epa and dha |
CN108778284A (zh) * | 2017-02-09 | 2018-11-09 | S.L.A.制药股份公司 | 高纯度游离脂肪酸二十碳五烯酸减少溃疡性结肠炎患者粪便钙卫蛋白水平及预防临床复发 |
CN107006809B (zh) * | 2017-04-11 | 2020-06-09 | 江南大学 | 一种有降血脂作用的醋洋葱制品及制备方法 |
JP7099821B2 (ja) * | 2017-12-20 | 2022-07-12 | ポッカサッポロフード&ビバレッジ株式会社 | Pcsk9阻害剤及びコレステロール代謝改善用食品組成物 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004098311A1 (en) * | 2003-05-05 | 2004-11-18 | Denofa As | Fish oils with an altered fatty acid profile, method of producing same and their use |
EP1656839A1 (en) * | 2004-11-11 | 2006-05-17 | N.V. Nutricia | Nutrition containing lipid blend |
US7884131B2 (en) * | 2004-11-19 | 2011-02-08 | Martek Biosciences, Corporation | Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same |
EP1714564A1 (en) * | 2005-04-21 | 2006-10-25 | N.V. Nutricia | Method for treatment and prevention of respiratory insufficiency |
WO2007058523A1 (en) * | 2005-11-17 | 2007-05-24 | N.V. Nutricia | Composition with docosapentaenoic acid |
KR100684642B1 (ko) * | 2006-09-14 | 2007-02-22 | 주식회사 일신웰스 | 어유 유래 글리세라이드 유지 조성물 및 이의 제조방법 |
BRPI1007518A2 (pt) * | 2009-02-10 | 2018-02-20 | Amarin Pharma, Inc. | uso de acido etil ester eicopentanoico para tratamento de hipertrigliceridemia |
NZ595204A (en) * | 2009-03-09 | 2014-11-28 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof |
US20110071090A1 (en) * | 2009-03-11 | 2011-03-24 | Stable Solutions Llc | Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle |
EP2424521A4 (en) * | 2009-04-29 | 2015-03-04 | Amarin Pharmaceuticals Ie Ltd | PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE |
US20110177061A1 (en) * | 2009-07-10 | 2011-07-21 | Martek Biosciences Corporation | Methods of treating and preventing neurological disorders using docosahexaenoic acid |
US8586567B2 (en) * | 2009-10-29 | 2013-11-19 | Acasti Pharma, Inc. | Concentrated therapeutic phospholipid compositions |
US20120302639A1 (en) * | 2011-02-16 | 2012-11-29 | Pivotal Therapeutics Inc. | Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death |
WO2013033618A1 (en) * | 2011-09-02 | 2013-03-07 | Arctic Nutrition As | Lipid compositions with high dha content |
AU2013277441B2 (en) * | 2012-06-17 | 2017-07-06 | Matinas Biopharma, Inc. | Omega-3 pentaenoic acid compositions and methods of use |
-
2013
- 2013-12-17 EP EP13878433.5A patent/EP2968246A4/en not_active Withdrawn
- 2013-12-17 WO PCT/US2013/075661 patent/WO2014143272A1/en active Application Filing
- 2013-12-17 JP JP2016500125A patent/JP2016518315A/ja active Pending
- 2013-12-17 CA CA2905671A patent/CA2905671A1/en not_active Abandoned
- 2013-12-17 WO PCT/US2013/075740 patent/WO2014143275A1/en active Application Filing
- 2013-12-17 WO PCT/US2013/075704 patent/WO2014158256A1/en active Application Filing
-
2014
- 2014-03-12 EP EP14779339.2A patent/EP2986148A2/en not_active Withdrawn
- 2014-03-12 CA CA2905795A patent/CA2905795A1/en not_active Abandoned
- 2014-03-12 JP JP2016501615A patent/JP2016512544A/ja active Pending
- 2014-03-12 WO PCT/US2014/024712 patent/WO2014165190A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2014143275A1 (en) | 2014-09-18 |
JP2016518315A (ja) | 2016-06-23 |
CA2905795A1 (en) | 2014-10-09 |
EP2986148A2 (en) | 2016-02-24 |
EP2968246A1 (en) | 2016-01-20 |
WO2014143272A1 (en) | 2014-09-18 |
EP2968246A4 (en) | 2016-08-03 |
JP2016512544A (ja) | 2016-04-28 |
WO2014158256A1 (en) | 2014-10-02 |
WO2014165190A2 (en) | 2014-10-09 |
WO2014165190A3 (en) | 2015-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210205254A1 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
US20140322314A1 (en) | Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment | |
CA2905671A1 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
AU2021201865A1 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
WO2014179341A1 (en) | Treatment with omega-3 fatty acid compositions | |
US20140194512A1 (en) | Compositions comprising docosapentaenoic acid and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |
Effective date: 20171219 |